Background. Prophylactic vitamin A supplementation (VAS) reduces mortality and may reduce morbidity associated with diarrhea in children 16 months of age. Rotavirus is the most common cause of acute dehydrating diarrhea among children worldwide.
tamin A deficiency-related breeches in gut integrity [3] . However, studies of the prophylactic effect of VAS on diarrhea-related morbidity have provided diverging results (reviewed in [4] [5] [6] ).
On the basis of studies from Indonesia [7] and India [8] that showed major reductions in infant mortality after administration of vitamin A at birth, we conducted a large randomized trial of vitamin A versus placebo given at birth in Guinea-Bissau to examine the effect on mortality in an African setting [9] . In this trial, we examined the effect of VAS on diarrhea disease during infancy and, in particular, whether VAS would reduce rotavirus infection and morbidity, because rotavirus is one of the leading causes of life-threatening diarrhea in infants in sub-Saharan Africa [10] .
PARTICIPANTS AND METHODS
Study site. The study was conducted at the Bandim Health Project, which established a demographic surveillance system in 6 districts in Bissau, the capital of Enrollment. From November 2002 through November 2004, infants were recruited for a randomized trial of vitamin A (50,000 IU) or placebo administered with bacille CalmetteGuérin (BCG) vaccine at birth. Newborns weighing у2500 g and not overtly sick who were reporting for BCG vaccination were recruited at the national hospital and at 2 local health centers in the Bandim Health Project study area. If participation in the study was accepted, the mother drew a lot determining whether the child should receive VAS or placebo with BCG vaccine. A total of 4345 infants were recruited in the cohort and were randomized to receive oral vitamin A (50,000 IU retinyl palmitate in vegetable oil with 20 IU vitamin E as antioxidant) or placebo (the same amount of vegetable oil and vitamin E). Vitamin A and placebo were prepared by a Danish pharmacy, which held the code until all children had been followed up for at least 1 year. Anthropometrics and background characteristics were collected at inclusion.
Rotavirus is epidemic in Guinea-Bissau from January through March [11] . The present diarrhea study was conducted during the annual rotavirus epidemic from January through March 2005. The exact timing of the epidemic was determined from hospital surveillance data and data from the present study. In December 2004, eligible infants were identified from the randomized cohort. Children were eligible if they were still living in 3 of 6 districts in the project area and if they were born after 20 May 2004. Older children were not considered, because they were likely to have received VAS in a national campaign targeting all children aged 6 months-5 years that was conducted during 18-20 November 2004 . Eligible children were visited weekly beginning in 20 December 2004, to obtain information on morbidity. Because enrollment in the randomized cohort ended in November 2004, the children were aged 1-7 months when they were first visited. During the 10-week epidemic, a weekly stool sample was collected irrespective of symptoms and was analyzed for presence of rotavirus antigen. Children not seen during the first 5 weeks of the epidemic were not included in the study.
Data and sample collection. At the weekly visits, a trained field assistant interviewed the caretaker, preferably the mother, about symptoms presented by the child in the preceding 7 days. Seven days of recall was allowed. Each day during the epidemic was then classified as "with diarrhea," "without diarrhea," or "not under observation." Missing observation time arose in 2 ways: if holidays, illness, or workload made the assistant postpone the weekly visit by 1-3 days, the days exceeding the allowed 7-day recall period were recorded as "not under observation;" if a child was absent or traveling and, thus, not seen, the days since the last successful visit were recorded as "not under observation."
At the interview, a tube for collecting a fecal sample was given to the caretaker, and the caretaker was instructed to obtain a sample at the first opportunity. Later the same day or the next morning, the assistant returned to collect the sample. If the caretaker had not obtained a sample, the assistant per- In the analysis of rotavirus infection, days at risk were observed days before the first episode of infection. In the analysis of rotavirus diarrhea, days at risk were all diarrhea-free days except the 2 days immediately after an episode. CI, confidence interval; IRR, incidence rate ratio; VAS, vitamin A supplementation.
Figure 2.
Cumulative incidence curves of rotavirus infection in infants aged 1-9.5 months. Top, Cumulative incidence appears to be higher than the observed incidence because the graph is constructed from pieces of risk time contributed by each child. No child contributed 110 weeks, and all risk time was during the epidemic. Thus, the curve can be regarded as the fictitious curve of cumulative incidence if the children had lived from 1 to 9.5 months of age in an epidemic situation. Bottom, One case in a very young male infant was omitted, because it occurred when very few children were under observation and, thus, resulted in an exaggerated large gap between the vitamin A supplementation and the placebo curves. If the case was included, the curves would look further apart. formed a rectal swab by insertion of a small sterile cotton swab into the rectum of the child for 5 s with a 180-degree rotation before removal. We previously found a concordance of 96% between results from rectal swabs and fecal samples [12] . The swab was placed in a clean transport tube. The tubes were kept refrigerated until analysis at the National Public Health Laboratory (Bissau, Guinea-Bissau). Children enrolled in the study who were hospitalized for diarrhea also had fecal samples examined for rotavirus. Laboratory methods. Samples were analyzed for rotavirus antigen at the National Public Health Laboratory with use of IDEA ELISA kits (DakoCytomation), in accordance with manufacturers' instructions.
Outcome definitions. The primary end points for the study were incidence of rotavirus infection, rotavirus-associated diarrhea, and nonrotavirus diarrhea. A child was considered to be infected with rotavirus when a stool specimen tested positive for rotavirus antigen by enzyme-linked immunosorbent assay (ELISA). A rotavirus infection was categorized as symptomatic if the child had diarrhea on the day of collection of the rotavirus-positive specimen, during the 3 preceding days, or during the 3 subsequent days. Infection was categorized as asymptomatic if the child did not have diarrhea at any time during this period.
A child was considered to have diarrhea if the caretaker reported diarrhea. An episode was defined as у1 consecutive day of reported diarrhea, beginning on the first day with symptoms and ending on the last symptomatic day, followed by 2 days without diarrhea or not under observation. If a day without symptoms or a day not under observation occurred during a diarrhea episode, the day was not considered to be part of that episode, but subsequent symptomatic days were included. For each diarrhea episode, a severity score was calculated. A scoring system was developed on the basis of the Vesikari score [13] , which was developed for rotavirus vaccine trial purposes, but significantly modified to fit available data (Table 1 , which appears only in the electronic version of the Journal).
Statistical methods. Rotavirus infection and diarrhea incidence and incidence rate ratios (IRRs) were examined using Cox proportional hazard models with age as underlying time and delayed entry. Therefore, the model only compared children of the same age, and thus, age was inherently controlled for and entry was delayed (ie, children only entered the analysis from the date of enrollment in the present study). Multiple events were allowed for diarrhea as outcome, obtaining robust variance estimates accounting for the dependence in individuals. The proportional hazard assumption was evaluated visually in log-log plots. We found nonproportional hazards by sex and by VAS. Consequently, we made separate estimates of the effect of VAS in boys and in girls aged !6 months and у6 months. Because of the timing of the rotavirus epidemic and the eligibility criteria, no child 19.5 months of age received NOTE. In the analysis of diarrhea incidence, days at risk were all diarrhea-free days except the 2 days immediately after an episode. CI, confidence interval; VAS, vitamin A supplementation.
follow-up. There were no VAS campaigns during the study. Children who moved outside the study area or died were censored at the time of the event.
Severity scores were compared for the control and the intervention group with use of a 2-tailed Student's t test of group means. All infants contributed with the same weight to the group mean irrespective of the duration of observation. Severity scores for rotavirus episodes versus nonrotavirus episodes were compared with the Wilcoxon rank-sum test. The relative risk (RR) of diarrhea among infants with rotavirus infection was calculated and tested using the x 2 test. Regression analysis was used to examine potential interactions. Because previous studies suggested sex-differential effects of VAS [7;14-16], we conducted the analyses separately for each sex. Analyses were performed using Stata, version 9.2 (StataCorp).
Ethical consideration. The protocol was approved by the Ministry of Health in Guinea-Bissau and the Danish Central Ethical Committee (624-02-0010). The study was registered in clinicaltrials.gov (NCT00168597). Participants in the trials had free access to medical consultations and essential drugs, including oral rehydration solution [9] .
Role of the funding sources. The sponsors had no role in the study design, data collection, data analysis, interpretation, or the writing of the report.
RESULTS
The rotavirus epidemic began on ∼1 January 2005. The present study covered the 10 weeks from 1 January through 13 March 2005. Of 316 children identified as eligible, 287 were recruited for the substudy: 136 from the vitamin A group and 151 from the placebo group (Figure 1) . The children were aged 1-9.5 months while the study was conducted. The baseline characteristics of the children and households were not significantly different between the randomization groups ( Table 2 ). All but 10 (5 from each randomization group) of the participating children were breastfed, and all were reported to be receiving supplementary water. Traveling is frequent in Bissau, and the period not under observation was comparable to that in other studies conducted in the study area. The mean duration ‫ע(‬ standard deviation) of follow-up (of 71 possible days) for the children was comparable in the 2 groups (vitamin A group: days; placebo group: days; ). 59.8 ‫ע‬ 1.2 61.2 ‫ע‬ 1.0 P p .34 Diarrhea and severity. The infants were symptomatic 8.3% of the time and experienced a mean of 1.15 episodes of diarrhea per 10 weeks at risk. Rotavirus was identified in 45 (17.3%) of 260 episodes of diarrhea; 2 children had rotavirus diarrhea twice. The percentage of samples testing positive for rotavirus was similar for fecal samples and rectal swab samples (data not shown). Rotavirus episodes were more severe than episodes of diarrhea without rotavirus ( ). The mean severity score P ! .01 was 1.5 in nonrotavirus episodes (median score, 1) and 3.2 in rotavirus diarrhea (median score, 3). The severity score was similar across randomization groups and in boys and girls.
Sex and age differential incidence of rotavirus infection and diarrhea. We detected rotavirus infection in 103 infants (35.9%) during the epidemic, and 43 had diarrhea at the same time. Boys were younger during the observed rotavirus infections and episodes of rotavirus diarrhea than girls; the median age for infection was 147 days for boys and 182 days for girls ( ) . The effect of sex on rotavirus infection and diarrhea P p .03 differed between the youngest and oldest children (Table 3 ). In the youngest age group, boys had higher incidence rates than did girls for both infection and diarrhea, whereas in the slightly older age group, girls had the highest incidence rate; the difference was highly significant for both infection and diarrhea (test of homogeneity of effect of age in boys and girls, P p and respectively). In accordance with these find-.006 P p .03 ings, all further analyses by sex were done separately for infants 1-5 months of age and for infants 6-9 months of age.
VAS and rotavirus infection and diarrhea. The effect of VAS on rotavirus infection and diarrhea was also found to be nonproportional with age. The incidence of rotavirus infection and diarrhea was significantly higher among VAS recipients than among placebo recipients in the youngest age group (age, !6 months). The IRR between VAS and placebo recipients was 1.72 (95% confidence interval [CI], 1.04-2.85) for rotavirus infection ( Figure 2 ) and 3.74 (95% CI, 1.40-9.98) for diarrhea. There was no effect of VAS among the children aged у6 months (Table 3) . For girls, VAS tended to be associated with increased risk of rotavirus infection and diarrhea in both age groups, whereas the effect in the youngest versus the oldest boys differed in direction. VAS tended to be deleterious in the younger group and, if anything, protective in the older group (test of homogeneity of effect in young vs older boys, ). P p .13 A considerable proportion of the children did not develop symptoms of diarrhea despite being infected with rotavirus (67% of children aged 1-5 months; 45% aged 6-9 months) ( Table 4 ). In the youngest age group, VAS recipients with rotavirus infection may have been more likely to develop symptoms than placebo recipients (RR, 2.38; 95% CI, 1.00-5.65). There was no difference in the older age group (RR, 0.86; 95% CI, 0.50-1.48).
Nonrotavirus diarrhea. The IRR for the effect of VAS versus placebo on nonrotavirus diarrhea in children aged !6 months was 0.74 (95% CI, 0.50-1.09), indicating that children in the VAS group had a slightly lower incidence than did children in the placebo group. In children у6 months of age, the IRR was 1.37 (95% CI, 0.87-2.16) ( Table 4) . VAS was associated with decreased incidence and prevalence of nonrotavirus diarrhea in boys and a tendency for increased incidence and prevalence in girls (Table 5 and Figure 3) ; the interaction between treatment group and sex was statistically significant ( ). The proportional hazard assumption was P p .03 therefore examined for each sex separately. Again, hazards were nonproportional. The beneficial effect for boys on nonrotavirus diarrhea was only found among the youngest children (IRR among boys !6 months of age, 0.51; 95% CI, 0.27-0.95), whereas the tendency for a negative effect of VAS among girls was only found among the oldest children (IRR in girls у6 months of age, 1.84; 95% CI, 0.96-3.55).
DISCUSSION
Contrary to expectations, VAS did not reduce rotavirus infection and rotavirus diarrhea; VAS was associated with a significantly higher incidence of rotavirus infection and diarrhea in the youngest children. A large proportion of the children had asymptomatic rotavirus infection during infancy in GuineaBissau. VAS may have increased the percentage of young children who developed symptoms. There was no overall effect of VAS on nonrotavirus diarrhea, but the effect differed significantly by sex (VAS was beneficial in boys but not in girls).
The high proportion of asymptomatic infection among children !6 months of age is likely to be attributable to protection by maternal antibodies [17] . However, the proportion was also high among older children. Overall, we found that 42% of the infants developed diarrhea during their primary rotavirus infection. Similar figures were observed in Mexico, where 47% of children aged 0-2 years were reported to be symptomatic during their first rotavirus infection [18] .
Studies conducted in Mexico that involved older children have shown that VAS is associated with a reduced prevalence and duration of enteropathogenic Escherichia coli and norovirus diarrhea but failed to show an overall reduction of prevalence and incidence of enterotoxigenic E. coli diarrhea [19, 20] . Analysis of subgroups of norovirus revealed a reduction in the incidence of norovirus GII infection; however, at the same time, VAS increased the duration of virus shedding of norovirus GI and GII. Furthermore, VAS was associated with increased duration of Giardia lamblia diarrhea. The authors argue that the pathogen-and genogroup-specific divergent outcomes could be attributable to differential regulation of the innate and adaptive immune response by vitamin A [20] . Our results support this hypothesis.
On the basis of previous studies, we expected that VAS at birth would reduce infant mortality and that reduction in the incidence of diarrhea might be one of the mechanisms underlying this effect. However, we did not find the expected reduction in infant mortality in the mortality study conducted in the randomized cohort [9] ; the mortality rate ratio (the mortality rate among VAS recipients divided by the mortality rate among placebo recipients) was 1.07 (95% CI, 0.79-1.44) [9] . Simultaneously, a study from Zimbabwe reported an essentially identical result of 1.08 (95% CI, 0.80-1.46) for VAS, compared with placebo [21] . Of interest, in Guinea-Bissau, the effect of VAS on mortality was slightly beneficial for boys but not for girls (mortality rate ratio, 0.84 [95% CI, 0.55-1.27] vs 1.39 [95% CI, 0.90-2.14]) [9] . A similar pattern of better effect for boys than for girls was documented in the 2 Asian trials of VAS given at birth [7, 8] , whereas the Zimbabwean study did not report results by sex [16] .
Although our study of diarrhea was small, it seems unlikely that the effect was merely a random event. The higher nonrotavirus diarrhea incidence associated with VAS and the higher incidence of rotavirus diarrhea among girls was consistent with the effect of VAS on mortality. Therefore, explaining the unexpected result of this diarrhea study may be parallel to understanding why VAS given at birth did not have the expected beneficial effect on survival. Furthermore, it should be recognized that the higher incidence of rotavirus diarrhea among younger boys contrasts with the observed effect of VAS on nonrotavirus diarrhea incidence and mortality.
An increasing number of studies have found sex-differential effects of VAS on vaccine responses [22, 23] , morbidity [7, 24] , and mortality [7, 9, 15, 16] , with a more beneficial effect among infant boys than among infant girls. During the conduct of the VAS trial, a measles epidemic occurred, and VAS was also associated with a significant sex-differential effect: the incidence of measles infection was reduced among boys but increased among girls (authors' unpublished data). The results of the present study were consistent with this tendency.
It could be speculated that the sex-differential effect of VAS could be attributable to sex differences in vitamin A status. However, girls did not have better vitamin A status than boys at 6 weeks or 4 months of age in a subgroup study of retinol binding protein levels in children from the randomized cohort [25] . On the contrary, boys had slightly better vitamin A status at 4 months of age [25] . Introduction of supplementary foods and weaning patterns did not differ by sex (data not shown).
In conclusion, in contrast to our initial assumptions, VAS at birth did not reduce rotavirus-related morbidity and nonrotavirus diarrhea. VAS was associated with an increase in rotavirus infection during the first 6 months of life. Diarrhea-related morbidity among boys !6 months of age was substantially decreased, but not because of increased resistance to rotavirus. Although VAS may treat or prevent vitamin A deficiency, the effect of VAS on mortality and diarrhea-related morbidity may not be beneficial for girls.
